Response to cyclosporin A and recombinant human erythropoietin in a case of B cell chronic lymphocytic leukemia and pure red cell aplasia.
Cesana
C
C
Carlo-Stella
C
C
Mangoni
L
L
Almici
C
C
Giachetti
R
R
Zappa
M
M
Rizzoli
V
V
D000368:Aged; D000369:Aged, 80 and over; D001803:Blood Transfusion; D002699:Chlorambucil / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use*; D004921:Erythropoietin / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000150:complications / Q000628:therapy*; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D011990:Receptors, Transferrin / Q000032:analysis; D011994:Recombinant Proteins / Q000627:therapeutic use; D012010:Red-Cell Aplasia, Pure / Q000097:blood / Q000150:complications / Q000628:therapy*; D017701:Reticulocyte Count
D006454:Hemoglobins; D011990:Receptors, Transferrin; D011994:Recombinant Proteins; D004921:Erythropoietin; D002699:Chlorambucil; D016572:Cyclosporine; D011241:Prednisone